P&G completes acquisition of Merck KGaA’s OTC divisionProcter & Gamble (P&G) has completed its acquisition of Merck KGaA’s Consumer Health business, in a move it Share XP&G completes acquisition of Merck KGaA’s OTC divisionhttps://pharmaphorum.com/news/pg-completes-acquisition-merck-kgaas-otc-division/
AbbVie, Pfizer reach licencing agreement for biosimilar HumiraAbbVie has granted a non-exclusive patent license allowing Pfizer to sell its Humira (adalimumab) biosimilar in many countries Share XAbbVie, Pfizer reach licencing agreement for biosimilar Humirahttps://pharmaphorum.com/news/abbvie-pfizer-reach-licencing-agreement-for-biosimilar-humira/
Pfizer strikes deal with Chinese online pharmacy JiankePfizer is set to implement a new retail, hospital services and internet healthcare strategy in China as part Share XPfizer strikes deal with Chinese online pharmacy Jiankehttps://pharmaphorum.com/news/pfizer-chinese-online-pharmacy-jianke/
Celgene scores at ASH18 with double luspatercept dataA pair of clinical trial wins for Celgene’s luspatercept at the American Society of Haematology (ASH) meeting have Share XCelgene scores at ASH18 with double luspatercept datahttps://pharmaphorum.com/news/celgene-scores-at-ash18-with-double-luspatercept-data/
New tech allows mobile-based eye testsUS ophthalmology technology firm EyeQue has launched VisionCheck, which it says is the world’s first automated optical device Share XNew tech allows mobile-based eye testshttps://pharmaphorum.com/news/new-tech-allows-mobile-based-eye-tests/
NHS funds BMS’ Opdivo to prevent skin cancer returningNICE has recommended interim NHS funding for Bristol-Myers Squibb’s cancer immunotherapy, Opdivo to prevent early stage skin cancer Share XNHS funds BMS’ Opdivo to prevent skin cancer returninghttps://pharmaphorum.com/news/nhs-funds-bms-opdivo-to-prevent-skin-cancer-returning/
Astellas scores first US blood cancer approval with XospataThe FDA has approved Astellas’ Xospata for certain patients with acute myeloid leukaemia – the company’s first drug Share XAstellas scores first US blood cancer approval with Xospatahttps://pharmaphorum.com/news/astellas-scores-first-us-blood-cancer-approval-with-xospata/
Alkermes preps filing for weight-friendly schizophrenia drugAlkermes is planning to head to the FDA next year with a new schizophrenia drug that, according to Share XAlkermes preps filing for weight-friendly schizophrenia drughttps://pharmaphorum.com/news/alkermes-preps-filing-for-weight-friendly-schizophrenia-drug/
NICE approves Bayer’s liver cancer drugNICE has given Bayer’s advanced liver cancer therapy Stivarga (regorafenib) the go-ahead after it undertook a rapid review Share XNICE approves Bayer’s liver cancer drughttps://pharmaphorum.com/news/nice-approves-bayers-liver-cancer-drug/
